Nepadutant

Chemical compound

Nepadutant (INN) (code name MEN-11420) is a glycosylated bicyclic cyclohexapeptide drug which acts as a highly selective NK₂ receptor antagonist.^[2][3][4] It was developed by the Menarini Group and investigated for the treatment of functional gastrointestinal disorders and asthma but was never marketed.^[3][5][6]

See also

• GR-159,897
• Ibodutant
• Saredutant

References

1. Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1999. pp. 56–. ISBN 978-0-08-058378-5.
2. Holzer P (17 June 2004). Tachykinins. Springer. pp. 224–226. ISBN 978-3-540-20690-3.
3. Regitz-Zagrosek V (2 October 2012). Sex and Gender Differences in Pharmacology. Springer Science & Business Media. pp. 489–. ISBN 978-3-642-30726-3.
4. Royal Society of Chemistry (Great Britain) (January 2003). Amino Acids, Peptides and Proteins. Royal Society of Chemistry. ISBN 978-0-85404-242-5.
5. Frank B (29 June 2011). Women's Issues in Gastroenterology, An Issue of Gastroenterology Clinics. Elsevier Health Sciences. pp. 54–55. ISBN 978-1-4557-1220-5.
6. Jancso G (27 November 2008). Neurogenic Inflammation in Health and Disease. Elsevier. pp. 297–. ISBN 978-0-444-53229-9.